NDA 201292 · Boehringer Ingelheim
Gilotrif
Afatinib Dimaleate · Oral · Kinase Inhibitor
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Apr 7, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Jul 12, 2013
Approved uses
5
Original approval plus efficacy supplements
Registered trials
209
22 Phase 3, 13 recruiting
FAERS reports
6,622
5,732 serious, 1,475 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 13, 2025.
GILOTRIF is a kinase inhibitor indicated for: First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test ( 1.1 ) Limitations of Use : Safety and efficacy of GILOTRIF were not established in patients whose tumors have resistant EGFR mutations ( 1.1 ) Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy ( 1.2 ) 1.1 EGFR Mutation-Positive, Metastatic Non-Small Cell Lung Cancer GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) , Clinical Studies (14.1) ]. Limitations of Use : The safety and efficacy of GILOTRIF have not been established in patients whose tumors have resistant EGFR mutations [see Clinical Studies (14.1) ]. 1.2 Previously Treated, Metastatic Squamous NSCLC GILOTRIF is indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy .
Mechanism: Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling. Certain mutations in EGFR, including non-resistant mutations in its kinase domain, can result in increased autophosphorylation of the receptor, leading to receptor activation, sometimes in the absence of ligand binding, and can support cell proliferation in NSCLC. Non-resistant mutations are defined as those occurring in exons constituting the kinase domain of EGFR that lead to increased...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 7, 2022 Supplement 17 · Efficacy · priority review OrphanLetterLabel
- Jan 12, 2018 Supplement 14 · Efficacy · priority review OrphanLabelLetter
- Apr 15, 2016 Supplement 7 · Efficacy LabelLetter
- Nov 9, 2015 Supplement 6 · Efficacy OrphanLetterLabel
- Jul 12, 2013 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewSummary ReviewLetter
3 products under this application
- GILOTRIF · AFATINIB DIMALEATE EQ 30MG BASE · TABLET, ORAL · Prescription · TE AB
- GILOTRIF · AFATINIB DIMALEATE EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
- GILOTRIF · AFATINIB DIMALEATE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Afatinib Dimaleate" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or GefitinibPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01085136 · 1,154 participants · Start Feb 2010 · Primary completion Oct 2013
Drug: Investigator´s choice of chemotherapy; BIBW 2992 · For: Carcinoma, Non-Small-Cell Lung
Sites: Buenos Aires, Argentina; Kingswood, Australia; South Brisbane, Australia · 97 sites in all
- LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based ChemotherapyPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01523587 · 795 participants · Start Mar 5, 2012 · Primary completion Oct 21, 2013
Drug: afatinib; erlotinib · For: Carcinoma, Non-Small-Cell Lung
Sites: Chandler, Arizona; La Jolla, California; Sacramento, California · 192 sites in all
- Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Active, not recruiting
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT03785249 · 731 participants · Start Jan 15, 2019 · Primary completion Jun 23, 2026
Drug: MRTX849; Pembrolizumab and 2 more · For: Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 222 sites in all
- LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapyPivotal-lookingTerminated
Boehringer IngelheimBoehringer Ingelheim
NCT01345669 · 617 participants · Start Oct 17, 2011 · Primary completion Sep 12, 2016
Drug: Placebo; Afatinib · For: Head and Neck Neoplasms
Sites: Little Rock, Arkansas; Orange, California; Aurora, Colorado · 162 sites in all
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruiting
AmgenAmgen (AMGN)
NCT04185883 · 610 participants · Start Dec 17, 2019 · Primary completion Dec 17, 2026
Drug: Sotorasib; Trametinib and 14 more · For: Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Sites: Tucson, Arizona; Duarte, California; La Jolla, California · 90 sites in all
- BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00656136 · 585 participants · Start Apr 2008 · Primary completion Oct 2013
Drug: placebo; BIBW 2992 · For: Carcinoma, Non-Small-Cell Lung
Sites: Kingman, Arizona; Fayetteville, Arkansas; Anaheim, California · 90 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea2,128
- malignant neoplasm progression1,696
- rash884
- death524
- nausea488
- stomatitis486
- decreased appetite450
- vomiting410
- paronychia355
- dehydration317
- fatigue292
- off label use283
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 5 |
| 2013 | 122 |
| 2014 | 503 |
| 2015 | 744 |
| 2016 | 794 |
| 2017 | 731 |
| 2018 | 936 |
| 2019 | 645 |
| 2020 | 582 |
| 2021 | 456 |
| 2022 | 343 |
| 2023 | 283 |
| 2024 | 214 |
| 2025 | 161 |
| 2026 | 103 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Gilotrif (Afatinib Dimaleate)
2024 spending
$61.1M
Beneficiaries
940
5,410 claims
Per beneficiary
$65,026
$377.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $44,968,931 |
| 2021 | $41,065,614 |
| 2022 | $44,799,472 |
| 2023 | $51,441,559 |
| 2024 | $61,124,499 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- New drug candidates for osteosarcoma: Drug repurposing based on gene expression signature.
Andrade RC, Boroni M, Amazonas MK, et al. · Comput Biol Med 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacokinetic and Safety Comparison of 2 Afatinib Dimaleate Tablets in Healthy Chinese Volunteers Under Fasted Conditions: A Randomized, Open-Label, 2-Period, Single-Dose Crossover Study.
Shi P, Jiang X, Tao Y, et al. · Clin Pharmacol Drug Dev 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Bioequivalence study of two formulations of afatinib dimaleate tablets in healthy subjects under fasting conditions: A randomized, open-label, single-dose, crossover trial.
Liu Y, Lü L, Xu M, et al. · Int J Clin Pharmacol Ther 2024 · Randomized Controlled Trial, Comparative Study
- Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
Goss GD, Felip E, Cobo M, et al. · JAMA Oncol 2018 · Clinical Trial, Phase III, Multicenter Study
- LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer.
Köhler J, Schuler M · Future Oncol 2014 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.